Water tragedy puts drug firm on map

Article Abstract:

The E. coli outbreak in Walkerton, Canada is drawing attention to Synsorb Biotech, which is supplying the government with its experimental antiinfective treatment.

Antiinfective Preparations, Use of materials & supplies, Antibacterial & Antiseptic Preps, Care and treatment, Anti-infective agents, Water supply, Escherichia coli infections, Synsorb Biotech Inc.

---

When threats turn to firebombs, Canaccord cuts loose on client

Article Abstract:

Vancouver-based brokerage firm, Canaccord Capital Corp., has decided to forego doing business with UK based Phytopharm PLC, after receiving warnings from Animal Liberation Front. Canaccord was threatened with dire consequences in the event it chose to do business with Phytopharm, which has linkes with Huntingdon Life Sciences Group PLC. Huntington Life tests its products on animals.

United Kingdom, Financial Services, Finance and Insurance, DEPOSITORY INSTITUTIONS, Contracts & orders let, Financial services industry, Demonstrations and protests, Contract agreement, Canaccord Capital Corp., Phytopharm PLC, Animal rights activists

---

Medicure future hangs on key drug's lab results

Article Abstract:

The performance of MC-1 flagship drug developed by Medicure Inc., which is tested by Wnnipeg-based company, is analyzed. MC-1 that is a metabolite of vitamin B6 used to decrease damages caused to heart tissue is described.

Product development, Product information, Cardiovascular Preparations, Testing, Dosage and administration, Cardiovascular agents, Medicure Inc.

Similar abstracts:

• Abstracts: For first time, Coke puts kids of color on collectible cans. Reinemund faces Pepsi challenge
• Abstracts: American regulator to hold public hearings on rail industry. Rail rivals see light at the end of the tunnel
• Abstracts: Church groups urge audit of Talisman's code of ethics compliance. Talisman divestment campaign unpopular
• Abstracts: Three bank reports in one day is 'ridiculous,' analysts feel. Royal, B of M to reveal all fees paid to auditors
• Abstracts: Inco turns to Ottawa after Xstrata's $16.1-billion rival bid. Inco just missed out on AOL stock bonanza

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.